REG - AOTI, Inc. - California Medicaid Provider ID Awarded

AotiAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250721:nRSU8292Ra&default-theme=true

RNS Number : 8292R  AOTI, Inc.  21 July 2025

21 July 2025

 

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

California Medicaid Provider ID Awarded

 

By far the largest Medicaid state in US by enrolled population

 

Third state this year where the Company has been granted provider ID

 

Strong predicate reference site for CMS coverage and further states in
commercial roll out

 

AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable
healing of wounds and the prevention of amputations, today announces further
progress on its market access and commercial expansion strategy having
successfully been granted a new Provider ID in California. This will allow the
Company to start to secure insurers and obtain coverage for its TWO(2)(®)
therapy in the state and support the Company's growth in the latter part of
2026.

 

California is by far the largest Medicaid state by enrolled population with
14.7 million, or 38%, of the population covered by Medi-Cal, California's
specific Medicaid programme.(1) This is the third state this year where the
Company has been granted provider ID and is in line with its guidance of
adding two to three states per year.

 

Medicaid has evolved to become the largest government funded healthcare
program providing comprehensive coverage of health and long-term care to 83
million low-income people in the United States. Medicaid accounts for
one-fifth of all US health care spending and covers one quarter of the entire
population. Medicaid is jointly funded by states and the federal government
but is uniquely administered by each state within broad federal rules.(2)

 

Dr. Mike Griffiths, Chief Executive Officer & President of AOTI, Inc.,
said:

"I am delighted we have been granted Provider ID in our home State of
California, which is a significant milestone in our growth strategy and
further validation of the unique value proposition we deliver. Securing market
access in California is a major achievement and will allow us to begin to
deliver the clinical and cost saving benefits of our TWO(2)(®) therapy to
patients, providers and payors in the largest Medicaid market in the US,
establishing a strong predicate reference site for CMS coverage where the
process is already in progress and, for further states in the Company's
commercial roll out."

 

1.
https://www.chcf.org/resource/how-many-congressional-district-get-medi-cal-premium-subsidy-through-covered-california/
(https://www.chcf.org/resource/how-many-congressional-district-get-medi-cal-premium-subsidy-through-covered-california/)

2. https://www.kff.org/medicaid/issue-brief/10-things-to-know-about-medicaid/
(https://www.kff.org/medicaid/issue-brief/10-things-to-know-about-medicaid/)

 

ENDS

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer   +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer     ir@aotinc.net (mailto:ir@aotinc.net)

 Peel Hunt LLP (Nominated Adviser and Broker)

 Dr. Christopher Golden, James Steel           +44 (0)20 7418 8900

 FTI Consulting (Financial PR & IR)

 Ben Atwell, Simon Conway,                     +44 (0)20 3727 1000

 Natalie Garland-Collins                       AOTI@fticonsulting.com (mailto:AOTI@fticonsulting.com)

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomized controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalizations and 71 per cent reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA), Europe
(CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. TWO(2)(®) therapy has
also recently received positive recommendation from the Federal Joint
Committee of Gemeinsamer Bundesausschuss (G-BA) in Germany. Also see
www.aotinc.net (http://www.aotinc.net)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAAXEAFKSEAA